explore -WSS

explore

author：knowledge 2025-09-30 01:14:42 - browse：7

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Can we make enough H5N1 bird flu vaccine if there's a pandemic?

focus

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Wearables generate powerful data but its not useful to doctors, yet

Medicare bonuses could stop drug shortages under Senate plan

A pediatrician calls for Congress to pass the child tax credit deal

TikTok, Instagram influencers need more rules for drug ads

explore

explore

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Future doctors need a strong humanities education

Sports medicine is finally prioritizing gender equality

When prostate cancer spreads, where it goes matters

Alkermes shareholders re

Dana Farber says 6 studies to be retracted and 31 corrected

Anesthesiologist group: stop taking Ozempic before surgery

Dana Farber says 6 studies to be retracted and 31 corrected

Guidelines to prevent youth baseball injuries need more muscle

Prior authorization reform is both possible and imperative

knowledge

It's time to retire 'poor historian' from clinicians' vocabularies

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Head of FDA's diagnostics center, who led through Covid, retires

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Second House panel advances two

Maisha Meds is a PBM, but don't call it that

focus

leisure time

focus

knowledge